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ABSTRACT 
Evaluation of the antinociceptive, anti-inflammatory and antipyretic activities of Ruta 
graveolens L. in mice and rats 
FIRDOWS LOONAT 
M. Pharm. Pharmaceutical Sciences thesis: School of Pharmacy, University of the Western 
Cape 
Ruta graveolens (Rutaceae) L. is a medicinal plant that is commonly used to manage and 
treat essential events such as pain, inflammation and fever. Despite its popularity, particularly 
as a medicinal plant in the Calvinia district and Bredasdorp region of South Africa, scientific 
data to substantiate its widespread traditional use and the possible mechanisms of action for 
this plant species is lacking. Therefore, the objectives of this study were: to scientifically 
evaluate and validate the antinociceptive, anti-inflammatory and antipyretic activities of Ruta 
graveolens using the acetic-acid writhing test and hot-plate test, the carrageenan rat paw 
oedema test, and the E. coli-induced pyrexia test, respectively; to investigate the possible 
mechanisms of the antinociceptive, anti-inflammatory and antipyretic activities of the plant 
using interaction studies; to determine some secondary metabolites present in the plant 
species using standard phytochemical analytical procedures; to characterise the plant species 
using HPLC techniques; and to determine the safety profile of the plant species using an 
acute toxicity study. 
Three percent (3 %) acetic acid (0.25 ml, i.p.) produced a substantial number of writhes in 
mice. The leaf methanol extract of Ruta graveolens (100 mg/kg, i.p.) significantly reduced 
the number of writhes induced by 3 % acetic acid (0.25 ml, i.p.). R. graveolens (100 mg/kg, 
i.p.) produced 54 % inhibition of 3 % acetic acid-induced writhes. Indomethacin (20 mg/kg, 
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i.p.) and paracetamol (500 mg/kg, i.p.) significantly reduced the number of 3 % acetic acid-
induced writhes. Indomethacin (20 mg/kg, i.p.) and paracetamol (500 mg/kg, i.p.) produced 
57 % and 80 % inhibition of 3 % acetic acid-induced writhes, respectively. R. graveolens (25 
– 50 mg/kg, i.p. and 200 – 400 mg/kg, i.p.) and indomethacin (10 mg/kg, i.p.) did not 
significantly reduce the number of writhes induced by 3 % acetic acid. However, combined 
therapy of the leaf methanol extract of R. graveolens (25 mg/kg, i.p.) and indomethacin (10 
mg/kg, i.p.) significantly reduced the number of 3 % acetic acid-induced writhes. The 
combined therapy of the lowest and sub-effective doses of the leaf methanol extract of R. 
graveolens (25 mg/kg, i.p.) and indomethacin (10 mg/kg, i.p.) produced 59 % inhibition of 
the writhes elicited by 3 % acetic acid. The leaf methanol extract of R. graveolens (50 – 400 
mg/kg, i.p.) greatly delayed the reaction time in mice to thermal stimulation produced with 
hot-plate. 50 – 400 mg/kg (i.p.) of the leaf methanol extract of R. graveolens significantly 
antagonised rat paw oedema induced by 1 % carrageenan (0.1 ml, subplantar) over the 4 h 
period of testing. In addition, indomethacin (10 mg/kg, i.p.) significantly antagonised 1 % 
carrageenan-induced rat paw oedema. R. graveolens (25 mg/kg, i.p.) and indomethacin (2 
mg/kg, i.p.) given separately did not significantly alter rat paw oedema induced by 1 % 
carrageenan. However, combined therapy of the leaf methanol extract of R. graveolens (25 
mg/kg, i.p.) and indomethacin (2 mg/kg, i.p.) significantly reduced 1 % carrageenan-induced 
rat paw oedema. The leaf methanol extract of R. graveolens (400 mg/kg, i.p.) significantly 
reduced the mean rectal temperature of normothermic rats. Ruta graveolens (100 – 400 
mg/kg, i.p.) significantly reduced pyrexia induced by E. coli (50 μg/kg, i.m.) over the 5 h 
period of testing. In addition, pentoxifylline (50 mg/kg, i.p.) significantly reduced E. coli-
induced pyrexia. Ruta graveolens (25 – 50 mg/kg, i.p.), paracetamol (500 mg/kg, i.p.) and 
pentoxifylline (10 mg/kg, i.p.) did not significantly reduce pyrexia induced by E. coli. 
However, combined therapy of the leaf methanol extract of R. graveolens (25 mg/kg, i.p.) 
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and pentoxifylline (10 mg/kg, i.p.) significantly reduced E. coli (50 µg/kg, i.m.)-induced 
pyrexia. 
The phytochemical studies of the powdered leaves of Ruta graveolens indicated the presence 
of alkaloids, cardiac glycosides, flavonoids, saponins, tannins and triterpene steroids. The 
HPLC fingerprint indicated characteristic peaks at the following retention times; 1.654 min, 
2.271 min, 2.403 min, 4.705 min and 7.691 min. The LD50 obtained for Ruta graveolens after 
oral administration was probably greater than 4000 mg/kg which shows that the plant extract 
is non-toxic to mice. 
In conclusion, the data obtained indicate that Ruta graveolens possesses antinociceptive, anti-
inflammatory and antipyretic activities. Since prostaglandins have been shown to mediate 
acetic acid-induced writhes, prostaglandins, histamine, serotonin, capsaicin and bradykinin 
implicated in carrageenan-induced rat paw oedema, and tumor necrosis factor-α (TNF-α) 
implicated in E.coli-induced pyrexia, it is possible that R. graveolens may be producing its 
antinociceptive, anti-inflammatory and antipyretic activities by affecting these chemical 
mediators. The data obtained also justify the use of the plant species by traditional medicine 
practitioners for the treatment of painful and inflammatory conditions, and pyrexia.  
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CHAPTER 1 
INTRODUCTION 
 
For centuries traditional medicine was the only system available for health care in the 
diagnosis, prevention and treatment of illnesses (WHO, 2003).  Increasing in popularity and 
acceptance in African communities, traditional medicine continues to grow (Cohen, 2003; 
WHO, 2003). The World Health Organisation (WHO) defines traditional medicine as the 
total combination of knowledge and practices, whether explicable or not, used in diagnosing, 
preventing or eliminating physical, mental or social diseases and which may rely exclusively 
on past experience and observation handed down from generation to generation, verbally or 
in writing (WHO, 2003). 
 
Traditional medicine is a comprehensive term that broadly encompasses traditional medicine 
systems such as Chinese medicine, Indian ayurveda and Arabic unani medicine, and various 
forms of indigenous medicine. Traditional medicine varies from country to country and 
region to region (WHO, 2012; Sofowora, 1982). African traditional medicine systems are 
mainly passed on from generation to generation via word of mouth. However, valuable 
traditional knowledge is lost or has been lost as a result of this practice (Light et al., 2005; 
Williamson et al., 1996). Literature indicates though that over the last three hundred years, 
references to indigenous materia medica were found in early European and other travellers’ 
accounts in southern Africa (Light et al., 2005; van Wyk et al., 1997). The most important of 
these documentations is that of Watt and Breyer-Brandwijk (1962) first published in 1932. 
This indigenous botanical medicine manuscript provides comprehensive data on medicinal 
plants of the southern and eastern African regions, and comprises of valuable reference 
material (Light et al., 2005).  
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Rich in plant diversity, Southern Africa accounts for almost 10 % of the world’s higher 
plants. Out of the 30 000 species of higher plants, 3000 of these have been used across the 
country as traditional medicine (Thring et al., 2005; van Wyk et al., 1997). Despite the use of 
orthodox medicine in the treatment and management of diseases, an estimated 70% of the 
South African population in both rural and urban areas rely on the use of plants for medicinal 
purposes (Light et al., 2005; Tabuti et al., 2003; Amabeoku et al., 1998). One of such plants 
is Ruta graveolens L. 
 
R. graveolens has been used to treat many conditions ranging from central nervous system 
disorders to autoimmune diseases (van Wyk et al., 1997). R. graveolens is one of many plants 
used in the treatment of pain, inflammation and fever due to underlying conditions such as 
toothache and earache, autoimmune diseases and infections (Raghav et al., 2006; van Wyk et 
al., 1997). The use of the plant species, among other medicinal plants, as an effective and 
potent medicine requires evaluation by standard scientific methods (Williamson et al., 1996). 
 
Therefore, R. graveolens was selected for comprehensive research to determine its 
phytochemical components, evaluate pharmacological activities, obtain an HPLC fingerprint, 
and perform toxicological studies to determine the safety profile of the plant species. Growth 
in scientific documentation is required to preserve knowledge of indigenous plant use for 
generations to come (van Wyk et al., 1997).  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Introduction 
2.1.1. Overview on Traditional Medicine 
During the years of early human existence, many plants were used to manage and treat 
diseases either by instinct, intuition, or trial and error. Humans sought to manage and treat 
disease with assistance, inspiration and guidance from their natural surroundings. Ancient 
cultures and communities developed their own materia medica as ideas of different tribes 
permeated each other, occasionally bringing together religion, rituals and magic (van Wyk et 
al., 1997). One of the earliest records of the use of herbal medicine is that of the Hydnocarpus 
Gaertn species. The Chaulmoogra oil derived from the plant species was effective in the 
treatment of leprosy, and this was recorded between 2730 and 3000 BC. Similarly, the castor 
oil seed (Ricinus communis L.) and the seed of opium poppy (Papaver somniferum L.) were 
unearthed from ancient Egyptian tombs, thereby indicating their use in Africa as far back as 
1500 BC. In addition, records found in Ebers papyrus also confirm the use of medicinal 
plants in Egypt at the time (Sofowora, 1982).  
 
The use of herbal medicine continued to grow for centuries, with many physicians recording 
and describing their herbal practices. However, it was not until 1785 that the leaves of 
foxglove (Digitalis purpurea L.) were found to be the active ingredient in a potion that was 
used for centuries to treat Dropsy – a condition of the heart that results in fluid retention and 
general swelling of the body. Since then the plant was thoroughly investigated, isolating the 
two active constituents digoxin and digitoxin, both official drugs in pharmacopoeia. These 
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are merely two of the many drugs used in the present day that have been derived from 
traditional plants (Sofowora, 1982).  
 
The system of traditional medicine is based on past experience and cultural beliefs and 
practices that have been handed down from generation to generation, verbally or in writing 
(WHO, 2012). Traditional medicine practitioners are people recognised by their communities 
as competent health care providers that use vegetable, animal, mineral substances and other 
methods taking inspiration from social, cultural, and religious backgrounds (WHO, 2012; 
Jäger et al., 2004; van Wyk et al., 2000; Sofowora, 1982). Traditional medicine practitioners 
are commonly known by the Zulu people as isangomas and inyangas (Perrott et al., 2003).  
 
Traditional medicine practitioners play an essential role in the health of millions of people. 
The exact number of these practitioners is difficult to assess due to them being unregulated, 
however, it is estimated that 250 000 practitioners provide health care to the South African 
population (Kayne, 2010; Perrott et al., 2003). In addition, the work force represented by 
traditional medicine practitioners is an essential resource for health-care coverage 
(Springfield et al., 2005). The socio-economic status of developing countries, the magnitude 
of health problems, and the few resources available make traditional medicine an essential 
matter to be viewed. Hence, there are many advantages to using traditional medicine: (1) it is 
cheaper than orthodox medicine, (2) it is more accessible to most of the population, (3) it is 
also more acceptable. Traditional medicine is also a potential source of new drugs or a cheap 
source of known drugs such as Montanoa tomentosa Cerv. used as a contraceptive. Also, 
obstacles such as time-consuming processes like compounding substances in a laboratory, are 
avoided in traditional medicine (Sofowora, 1982). 
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Despite these advantages, traditional medicine still faces many shortcomings, some of which 
include: (1) imprecise diagnosis often given by the practitioners, (2) lack of precise dosages 
of medicaments used, (3) criticism that traditional medicine practitioners are not hygienic in 
their practices, and witchcraft, and (4) evil aspects of traditional medicine can also be 
criticised. However, the greatest argument against traditional medicine is the lack of scientific 
proof of its efficacy (Springfield et al., 2005; Sofowora, 1982).  
 
In developing countries more than one third of the population lacks access to essential 
medicines (Kayne, 2010). In Africa, 80% of the population rely on traditional medicine to 
meet their primary health care needs (Kayne, 2010; Springfield et al., 2005). Presently, Africa 
comprises of approximately 52 states of which 46 of these states maintain vegetation ranging 
from lowland rain forest to semi-desert scrubland (Kayne, 2010). However, only a few 
African indigenous remedies have found their way into western pharmacopoeias. A 
pharmaceutical monograph for the African plant species belonging to the Rutaceae family 
appears in current and earlier editions of the British Pharmacopoeia, British Pharmaceutical 
Codex and European Pharmacopoeia (Kayne, 2010). Despite this, safety and efficacy data 
available for plants used in South Africa are few (Springfield et al., 2005). 
 
 
In order to enhance the safety and efficacy of plant medicines, there is the need for 
characterisation and standardisation of the plant materials. This can be achieved through 
phytochemical qualitative analysis, HPLC fingerprint and toxicity studies (Springfield et al., 
2005). 
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2.2. Phytochemical analysis 
Phytochemical tests aid in the screening of plants by employing methods for isolating and 
identifying constituents present in a plant species. In addition, the characterisation of an 
active constituent responsible for toxic or beneficial effects can be useful when using the 
plant extract in living systems. Methods used aid in identifying alkaloids, quinines, 
terpenoids, and so forth known as secondary metabolites that may contribute immensely to 
the effectiveness of the plant materials in therapy (Harborne, 1984). 
 
2.3. High performance liquid chromatography 
Chromatography may be defined as the separation of solutes in a mixture. These solutes are 
separated according to their affinity to the stationary phase, through which the mobile phase 
moves. Separation may occur through adsorption, partition, molecular diffusion or 
electrophoresis, or a combination of these (Williamson et al., 1996; Harborne, 1984). 
Chromatographic techniques include paper chromatography (PC), thin layer chromatography 
(TLC), gas liquid chromatography (GLC) and high performance liquid chromatography 
(HPLC).  
High accuracy and precision, ease of use, easy sample preparation, rapid analysis and high 
sensitivity make HPLC the fastest growing analytical technique. The solubility and volatility 
properties of compounds to be separated should be considered when choosing an appropriate 
chromatographic technique for the sample (Harborne, 1984). The HPLC technique may be 
used for less volatile constituents that need to be separated, example terpenoids, alkaloids and 
all types of phenolics (Harborne, 1984). In addition, HPLC with UV-detector is most useful 
when the solutes have pronounced ultraviolet absorption (Williamson et al., 1996). The 
successful separation of compounds is indicated by characteristic peaks at specific retention 
times. A chromatographic fingerprint presents the chemical characteristics of herbal 
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medicines. Samples with similar chromatographic fingerprints have similar properties (Fan et 
al., 2006). Chemical fingerprints allow phytochemical constituents of the plant species to be 
identified. (Bombardelli, 2001). 
 
2.4. Toxicity studies 
Therapeutic and toxic effects are determined by measuring the safety margin of compounds 
(Rang et al., 2012). Known as the therapeutic index (TI) or therapeutic ratio, it is a 
comparison dosage range between the dose producing the desired effect and the dose 
producing a lethal one (Rang et al., 2012; Loomis and Hayes, 1996). The TI is obtained 
experimentally from two dose-response curves using mice or rats. The maximum no-
observed-adverse-effect-level (NOAEL) is established using the dose-response curve. This 
provides a level of assurance to the researcher and regulatory authority on the safety of the 
test compound (Poole and Leslie, 1989). In addition, the LD50 can be obtained. The LD50 is 
the dose at which mortality of 50 % of the test population occurs. 
 
2.5. Analgesia 
2.5.1. Pain and Nociception 
Pain is considered to be an unpleasant sensory and emotional experience that is associated 
with actual or potential tissue damage, or described in terms of such damage. Pain is often 
classified as acute or chronic. The nature of pain also varies and may be described as 
pricking, stabbing, burning, throbbing, aching, and so forth. Pain is associated with impulse 
activity in the primary afferent fibres of peripheral nerves. These nerves have sensory endings 
in peripheral tissues that are activated by a variety of stimuli such as mechanical, thermal, 
and chemical (Rang et al., 2012).  
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Pain and nociception differ in that pain is a subjective experience that includes a strong 
emotional (affective) component, whereas nociception is the perception of noxious stimuli. It 
is the mechanism whereby noxious peripheral stimuli are transmitted to the central nervous 
system. There are many factors that contribute to the amount of pain that a particular stimulus 
produces (Rang et al., 2012; Webster and Jordan, 1989). A stabbing sensation in the chest 
will cause much more pain if it spontaneously occurs in an individual than if it occurs as a 
result of poking an individual in the ribs with a stick. The affective component differs to that 
of the nociceptive component (Rang et al., 2012). It is recognised clinically that many 
analgesics, particularly those of the morphine type, can reduce the distress associated with 
pain even though the patient reports no change in the intensity of the sensation. 
 
2.5.2. Pain Transmissions 
Pain is associated with impulse activity via small-diameter myelinated Aδ fibres and 
unmyelinated C-fibres and of peripheral nerves. Myelinated Aδ fibres convey sharp 
sensations of pain, whereas unmyelinated C-fibres convey a dull, diffuse, burning pain. These 
C-fibres are associated with polymodal nociceptive endings. Nociceptive information is 
conveyed via Aδ and C and fibres from muscle, viscera, and skin (Rang et al., 2012). 
Receptors found in the skin and subcutaneous tissue respond to stimuli such as touch, 
pressure, heat, cold, and pain. Nociceptors are sensory receptor neurons sensitive to noxious 
stimuli or tissue-damaging stimuli (Kierszenbaum, 2007). There are three categories of 
nociceptors namely; thermal, mechanical, and polymodal. Thermal receptors respond to 
temperatures less than 5ºC and higher than 45ºC. Mechanical nociceptors respond to tissue-
damaging mechanical stimuli, example a needle or tissue injury that is an immediate cause of 
pain (Kierszenbaum, 2007; Martin, 2012). Polymodal nociceptors respond to noxious thermal 
or mechanical stimuli (Kierszenbaum, 2007). 
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Tissue injury is the immediate cause of pain. Tissue injury results in the local release of 
chemicals such as bradykinin and kallidin that act on nerve terminals, either activating them 
or enhancing their sensitivity to other forms of stimulation. Prostaglandins are responsible for 
enhancing the pain-producing effect of an agent like bradykinin (Rang et al., 2012). Pain is 
transmitted from free nerve endings via a transduction process, synapsing in the spinal cord 
via myelinated Aδ fibres and the unmyelinated C-fibres. These free bared nerve endings, 
innervate various tissues as a result of their branched tree-like structures (Kierszenbaum, 
2007). 
 
Polymodal nociceptors (PMNs) are the main category of peripheral sensory neuron that 
responds to noxious stimuli. Most PMNs are unmyelinated C-fibres with nerve endings that 
respond to thermal, mechanical and chemical stimuli (Rang et al., 2012).  In the dorsal root 
ganglia lie the cell bodies of spinal nociceptive afferent fibres. These fibres enter the spinal 
cord via the dorsal roots, ending in the grey matter of the dorsal horn. Most of these 
nociceptive afferent fibres terminate in the superficial region of the dorsal horn, resulting in 
the formation of synaptic connections with transmission neurons running to the thalamus 
(Rang et al., 2012; Williamson et al., 1996). Glutamate, a fast transmitter and various 
peptides such as substance P are released by PMN neurons, acting as slow transmitters. 
Peptides are released peripherally and contribute to neurogenic inflammation (Rang et al., 
2012). 
 
Sensitisation of PMNs to prostaglandins, elicits the mechanism of action commonly used by 
pain killers and non-steroidal inflammatory drugs (Rang et al., 2012). These drugs act by 
blocking the action of cyclo-oxygenase which converts arachidonic acid to prostaglandins, 
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thereby preventing the sensitisation of receptors to alogenic substances (Webster and Jordan, 
1989). 
 
Various animal models for studying nociceptive activity exist (Williamson et al., 1996). 
These include: (1) Acetic acid writhing test used to study the peripheral effects of drugs 
acting against nociception; (2) Hot plate test and tail-flick test used to study the central 
antinociceptive effects of drugs. 
 
2.5.3. Pain management 
Standard analgesic drugs used in the management and treatment of pain fall into three 
categories namely; opioids, non-opioid analgesics, and non-steroidal anti-inflammatory drugs 
(Portenoy, 2000; SAMF, 2012). 
 
2.5.3.1. Opioid analgesics 
The term ‘opioid’ refers to any substance, whether endogenous or synthetic, that produces a 
morphine-like effect. Opioid analgesics may be classified as low-efficacy opioids, high-
efficacy opioids and intermediate-efficacy opioids, and are used for the relief of mild to 
moderate pain or severe chronic pain (Rang et al., 2012; SAMF, 2012). Examples of low-
efficacy opioids include codeine used to relieve mild to moderate pain, and 
dextropropoxyphene which has been withdrawn from the market as a result of increased risk 
to adverse cardiovascular events. Examples of high-efficacy opioids include morphine, a 
valuable opioid analgesic used to relieve severe painful conditions and methadone which has 
a long duration of action and may be used in the management of a non-productive cough in 
lung cancer (SAMF, 2012).  
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Opioids act as agonists by inhibiting the transmission of nociceptive impulses through the 
dorsal horn, subsequently suppressing nociceptive spinal reflexes. This occurs at specific 
opiate receptor binding sites in the central nervous system and other tissues (McCarver, 
2001). Opioid receptors are widely distributed in the limbic system, thalamus, striatum, 
hypothalamus, midbrain and the spinal cord (Rang et al., 2012; McCarver, 2001).  
 
2.5.3.2. Non-opioid analgesics 
Acetaminophen, classified as a non-opioid analgesic and also known as paracetamol, is one 
of the most commonly used analgesic-antipyretic agents with weak anti-inflammatory effects 
(Rang et al., 2012). Paracetamol is used for the relief of mild to moderate pain, or pyrexia. It 
is safe to use in pregnancy, and only interacts with oral anticoagulants such as warfarin 
(SAMF, 2012). According to Graham and Scott (2003) and Rang et al., (2012), Paracetamol 
is a weak inhibitor of cyclo-oxygenase (COX)-1 and COX-2 (Rang et al., 2012; Graham and 
Scott, 2003). Paracetamol is also a potent inhibitor of prostaglandin synthesis in intact cells 
(Graham and Scott, 2003). This is in the presence of low arachidonic acid concentrations. 
Despite the mechanism of action of paracetamol not being completely established, it is 
known to inhibit prostaglandin synthesis in the brain, but not peripherally, thereby explaining 
the lack of anti-inflammatory activity (SAMF, 2012). In addition, Snipes et al., (2005) 
proposed that an alternative COX isoform in dog brain, COX-3 and renamed COX-1b, exists. 
Furthermore, Ayoub et al., (2006) hypothesised that COX-1b was involved in the 
antinociceptive activity of paracetamol in mice.  
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2.5.3.3. Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are characteristic to aspirin with regard to 
analgesic, anti-inflammatory and antipyretic activities (SAMF, 2012). NSAIDs may be used 
for the symptomatic relief of mild to moderate pain and inflammation. Some examples of 
NSAIDs include aspirin, ibuprofen, and indomethacin which can be used in rheumatological 
disorders (Rang et al., 2012; SAMF, 2012).  NSAIDs inhibit cyclo-oxygenase, the enzyme 
responsible for prostaglandin synthesis. By competing for the active sites of cyclo-
oxygenases with arachidonic acid, NSAIDs inhibit the action of COX-1 and COX-2 (Katz, 
2002; Lee et al., 2005; Pinardi et al., 2005; SAMF, 2012). The analgesic activity of NSAIDs 
allow for the prevention of nociceptive nerve ending sensitisation to allogenic substances, 
thus producing analgesic activity (Webster and Jordan, 1989; Rang et al., 2012). 
 
2.6. Inflammation 
2.6.1. Introduction 
Inflammation occurs due to a characteristic series of changes that follow a damaged area after 
injury. The reaction may last for hours or even days (Hurley, 1972). There are five cardinal 
signs of inflammation that manifest themselves as Rubor (redness), Tumour (swelling), Calor 
(heat), Dolor (pain), and function laesa (loss of function). Appearances of inflammation that 
occur in living transparent tissues (injured) include changes in vascular calibre and flow, 
increased vascular permeability leading to the formation of protein-rich exudates and local 
oedema, and escape of leucocytes from circulating blood into the extravascular tissues 
(Hurley, 1972). The inflammatory response occurs in tissues subsequent to exposure to a 
pathogen or other noxious substance. Responses are usually protective. Mediators generated 
by cells or plasma modify and regulate the magnitude of the response (Rang et al., 2012; 
Kumar and Clark, 2009). 
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2.6.2. Inflammatory Process/Mediators 
The inflammatory process is initiated by the release of chemical mediators into extracellular 
fluid (Hoffman, 2003). Mediators are molecules that promote the enhancement of blood flow, 
increase vessel permeability, and induce emigration of inflammatory cells from blood into 
extravascular tissues. Once molecules have reached the site of injury, the cells are stimulated 
to phagocytise bacteria and debris. An inflammatory mediator is a chemical messenger that 
acts on blood vessels and/or cells to contribute to an inflammatory response, and can be 
classified as either an exogenous or an endogenous mediator. Mediators include histamine, 
serotonin, bradykinin, prostaglandin E2, leukotriene B4, platelet-activating factor, 
interleukin-1 (IL-1), and so forth (Larsen et al., 1983). 
 
There are various animal models for inflammation which can be used to study the effect of 
drugs. These include Rat hind paw oedema test, Inflammation of Rodent Ear and Adjuvant 
Arthritis in rat and mouse (Williamson et al., 1996). 
 
2.6.3. Anti-inflammatory Drugs 
All NSAIDs are characteristic of the prototype aspirin, having analgesic, anti-inflammatory 
and antipyretic activities. They may be used in the treatment of dental and bone pain, 
dysmenorrhoea and headaches (SAMF, 2012). NSAIDs include aspirin, ibuprofen, 
diclofenac, indomethacin and so on. Indomethacin may be used for the relief of pain and 
inflammation in rheumatological conditions, especially in patients that do not respond well to 
alternatives available (SAMF, 2012).  NSAID’s have the ability to inhibit cyclo-oxygenase 
(COX), the enzyme responsible for prostaglandin synthesis (SAMF, 2005). NSAIDs reduce 
components of the inflammatory and immune response in which prostaglandins play a 
significant role. This includes vasodilatation and oedema. COX inhibitors suppress 
 
 
 
 
14 
 
prostanoid synthesis in inflammatory cells through inhibition of COX-2 isoform of the 
arachidonic acid. COX-2 inhibitors include celecoxib and etoricoxib (Rang et al., 2012). 
Celecoxib may be used in the symptomatic relief of pain and inflammation in rheumatoid 
arthritis (SAMF, 2012). Furthermore, anti-inflammatory drugs include disease-modifying 
antirheumatic drugs such as auranofin, penicillamine and chloroquine. Auranofin inhibits the 
induction of IL-1 and tumour necrosis factor alpha (TNF-α), while the precise mechanism of 
action of penicillamine is still a matter of speculation. However, penicillamine is thought to 
modify rheumatic disease by decreasing the immune response, IL-1 generation, and 
preventing the maturation of newly synthesised collagen by affecting the synthesis of 
collagen (Rang et al., 2012). 
 
2.7. Pyrexia 
2.7.1. Introduction 
Pyrexia, also known as fever, is a physiological mechanism that is beneficially effective in 
fighting infections. This is the body’s way of retarding the growth and reproduction of 
bacteria and viruses, enhancing neutrophil production and T-lymphocyte proliferation, and 
aiding in the acute-phase reaction (Sullivan et al., 2011). Normal body temperature is 
regulated by the thermoregulatory centre in the anterior hypothalamus by controlling the 
balance between heat loss and heat production (Rang et al., 2012; Kumar and Clark, 2009). A 
disturbance in the hypothalamic ‘thermostat’ results in a fever, which leads to a rise in normal 
body temperature (Rang et al., 2012). Gram-negative bacteria may cause this rise in 
temperature. Toll-like receptors generate signals that lead to the formation of inflammatory 
cytokines IL-1, -6, -12, TNF-α and many others. These cytokines act on the thermoregulatory 
centre, thereby increasing prostaglandin-E2 synthesis (Kumar and Clark, 2009). 
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In animal models, pyrexia can be induced using Breuer’s yeast and lipopolysaccharides, 
bacterial endotoxins. Prostaglandins have been implicated in Breuer’s yeast-induced pyrexia 
while mediators such as TNF-α have been implicated in lipopolysaccharide-induced pyrexia 
(Santos and Rao, 1998; Williamson et al., 1996). 
 
2.7.2. Antipyretic drugs 
NSAIDs and the non-opioid analgesic, paracetamol, may be used in the treatment of pyrexia 
due to a mediator such as the prostaglandins. NSAIDs exercise their antipyretic action by 
inhibiting prostaglandin production in the hypothalamus. This inhibits the E-type 
prostaglandins from elevating the body’s temperature. COX inhibitors control pyrexia by 
inhibiting IL-1 from releasing prostaglandins in the central nervous system, thereby 
preventing an elevation in body temperature (Rang et al., 2012).   
 
Pain, inflammation and fever have been well managed and treated with the numerous 
effective orthodox medicines available. Despite this, plant medicines have also been used by 
traditional medicine practitioners especially in rural communities and also in urban and peri-
urban areas of South Africa to manage and treat these conditions. One such plant medicine 
widely used to treat pain, inflammation and fever is Ruta graveolens L. 
 
2.8. Description of the plant 
2.8.1. Introduction 
Ruta graveolens L, also known as Rue or the Herb of Grace in English, belongs to the 
Rutaceae family. It is native to Europe, but commonly grown in South Africa. It is commonly 
known in Afrikaans as “wynruit or binnewortel.” Ruta is a woody, evergreen shrub of up to a 
metre in height with a characteristic aromatic scent. The plant has yellow flowers that are 
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made up of 4 petals each. The leaves are irregularly divided into hairless leaflets that have 
translucent glands (van Wyk et al., 1997). These leaves can be used fresh or dried for 
medicinal purposes.  
 
Parts of the plant that are used include the leaves and twigs. Leaf infusions are taken for 
fever, epilepsy and hysteria. Alcoholic tinctures have been used for respiratory problems and 
heart diseases. Bruised leaves are used for toothache and earache, while decoctions have been 
used to ease childbirth (van Wyk et al., 1997; Watt and Breyer-Brandwijk, 1962). 
Several plants of the Rutaceae family are used in traditional medicine worldwide for several 
therapeutic purposes (Raghav et al., 2006). In Italian traditional medicine Rutaceae is among 
the most used plant species, showing abundant use in ancient systematic record of medical 
practice, the Corpus Hippocraticum (Polio et al., 2008). A study conducted in Jordan on the 
effects of some medicinal plant extracts found that R. graveolens was one of the plant species 
used in Jordanian traditional medicine, showing anti-inflammatory activities (Atta et al., 
1998). Rue is a remedy for deep aching pain, rheumatism, headaches, dizziness, and fever 
(Cartaxo et al., 2010; Raghav et al., 2006). A study conducted in the Southern Overberg 
Bredasdorp region of South Africa, found that R. graveolens was one of the most commonly 
used plants by community members to treat ailments such as headaches, arthritis, fever, 
convulsions, and so forth (Thring et al., 2006). 
 
2.9. Objective of the study 
Even though various reports and studies have shown that R. graveolens has been widely used 
by traditional medicine practitioners and homeopaths to effectively treat headaches and other 
painful conditions, arthritis, fever among other ailments (Cartaxo et al., 2010; Thring et al., 
2006; Raghav et al., 2006; Atta et al., 1998; van Wyk et al., 1997, Watt and Breyer-
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Brandwijk, 1962), no literature exists on any study on the possible mechanisms of action of 
the plant species in painful conditions, inflammation and fever. The study intended, therefore, 
to:  
1. Verify the antinociceptive, anti-inflammatory and the antipyretic activities of R. 
graveolens by investigating the effects of the plant species against nociception 
induced by acetic acid and thermal method, inflammation induced by carrageenan and 
pyrexia induced by lipopolysaccharide, a bacterial endotoxin, respectively. 
2. Investigate the possible mechanisms of the antinociceptive, anti-inflammatory and 
antipyretic activities using interaction studies. 
3. Carry out phytochemical qualitative analysis to determine some of the secondary 
metabolites present in the plant species. 
4. Carry out an HPLC study in order to characterise the plant species. 
5. Carry out an acute toxicity study in an attempt to establish the safety profile of R. 
graveolens.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. Plant materials 
3.1.1. Selection, collection and identification of plant material 
R. graveolens L. was selected based on its therapeutic claims by traditional medicine 
practitioners for its useful antinociceptive, anti-inflammatory and antipyretic activities. 
Freshly picked leaves and twigs of the plant species were bought from Herb Organic 
Gardens, Robertson, Western Cape, Republic of South Africa. The plant species was 
authenticated by a taxonomist in the Department of Biodiversity and Conservative Biology at 
the University of the Western Cape. A voucher specimen of R. graveolens (UWC 8968) was 
deposited in the Herbarium of the University. 
 
3.1.2. Preparation of leaf methanol extract of R. graveolens 
The fresh leaves and twigs of the plant species were weighed (2.5885 kg) and then dried in 
the oven at 35°C to 40°C for 2 days. The dried leaves and twigs were then weighed (1.0163 
kg) and ground to a fine powder using a laboratory miller. The fine powder obtained weighed 
968.2 g. A weighed quantity 50.0 g of the powder was extracted in a soxhlet extractor using 
methanol 500 ml as a solvent for 24 h. The methanol filtrate was evaporated to dryness using 
a Buchi RE II rotavapor and Buchi 461 water bath. The resultant semi-solid substrate was 
then frozen at - 80°C and freeze-dried (LSL Secfroid SR, Model 3021, Switzerland) for 5 
days. A yield of 9.4 g of dried leaf methanol extract was obtained and stored in a desiccator 
until further use. Fresh solution of the crude methanol extract was prepared on each day of 
the experiment by dissolving a given quantity of the methanol extract in a small volume of 
dimethylsulfoxide (DMSO) and made up to the appropriate volume with physiological saline. 
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The plant extract solution was administered in a volume of 1 ml/ 100g of the body weight of 
animals. 
 
3.2. Phytochemical analysis of R. graveolens 
The dried powdered leaf of the plant species was analysed for various chemical compounds 
using standard protocols of Ikhiri et al. (1992) and Harborne (1984). 
 
3.2.1. Alkaloids 
Powdered R. graveolens (0.5 g) was boiled with 10 ml of dilute hydrochloric acid (alcoholic) 
in a test tube for 5 min. The mixture was cooled and the debris was allowed to settle. The 
supernatant liquid was filtered and 1 ml of the filtrate was taken into another test tube to 
which 3 drops of Dragendorff’s reagent (potassium bismuth iodide solution) was added, 
shaken and observed for the appearance of an orange-red spot and a precipitate formation. 
 
3.2.2. Cardiac glycosides 
Powdered R. graveolens (0.5 g) was boiled in 5 ml of 70 % ethyl alcohol for 2 min. The 
mixture was filtered and 10 ml of water and 5 ml of chloroform were added to the filtrate. It 
was then shaken. The lower chloroform layer was separated off and evaporated to dryness in 
a water bath. The cooled chloroform residue was dissolved in 3 ml of glacial acetic acid 
containing 0.1 ml of ferric chloride. The solution was carefully transferred to the surface of 2 
ml of sulphuric acid and observed for a reddish-brown layer that was formed at the interface 
and whether the upper layer gradually acquired a bluish-green colour. 
3.2.3. Flavonoids 
Powdered R. graveolens (10 g) was boiled for 2 - 3 min in 100 ml of water in a water bath. 
To 3 ml of the filtrate, 3ml of acetic acid-alcohol (Ethanol:Water:Concentrated hydrochloric 
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acid in a ratio of 1:1:1), solid magnesium (1 cm) and 1 ml of t-amyl-alcohol were added. The 
mixture was then observed for a rose-orange or violet colour change. 
 
3.2.4. Quinones 
Powdered R. graveolens (0.1 g) was shaken in 10 ml of 15 % ferric chloride solution and 5 
ml of hydrochloric acid, and immersed in a water bath for 10 min. The mixture was filtered 
immediately. The filtrate was cooled and extracted with 10 ml of carbon tetrachloride. The 
carbon tetrachloride layer was separated, washed with 5 ml of water and shaken with 5 ml of 
dilute ammonia solution. The resultant mixture was observed for a rose pink to cherry red 
colour in the ammoniacal layer. 
 
3.2.5. Saponins 
Powdered R. graveolens (0.2 g) was shaken with water and the mixture was observed for a 
persistent froth. 
 
3.2.6. Tannins 
Powdered R. graveolens (0.2 g) was boiled in 5 ml of water. The mixture was cooled and 
filtered. To the filtrate, 3 drops of 5 % ferric chloride solution were added to the filtrate and 
observed for a blue-black precipitate formation. 
 
3.2.7. Triterpine steroids 
Powdered R. graveolens (1 g) was extracted for 24 hrs in ether. The filtrate (1 ml) was 
evaporated to dryness and the residue re-dissolved in several drops of acetic anhydride and 
then several drops of sulphuric acid were added to solution. The mixture was then observed 
for a green colour change. 
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3.3. Experimental animals 
Male and female albino mice and rats bred in the Animal House of the Discipline of 
Pharmacology, University of the Western Cape, Bellville, South Africa were used in this 
study. Mice weighing between 18 – 30 g, and rats between 180 – 210 g were used. Mice were 
used in groups of eight and rats in groups of six for the experiments. All the animals had 
access to food and water ad libitum. Prior to commencement of the experiments, the animals 
were fasted for 16 h but still had access to water. The laboratory in which experiments were 
performed was maintained at an ambient temperature of 22 ± 2°C. Alternate 12 h light and 12 
h dark cycle was also maintained. 
 
3.4. Drugs and chemicals 
Acetic acid (Merck) was dissolved in physiological saline to an appropriate volume. 
Indomethacin (Sigma Chemical Co.) was dissolved in a minimum amount of 
dimethylsulfoxide (DMSO, Sigma Chemical Co.) and made up to an appropriate volume with 
physiological saline. Carrageenan (Sigma Chemical Co.) was dissolved in physiological 
saline to an appropriate volume. Paracetamol (4-acetamidophenol, Sigma Chemical Co.) was 
dissolved in a minimum volume of propylene glycol and made up to an appropriate volume 
with physiological saline. Escherichia coli (E. coli, Sigma Chemical Co.) and pentoxifylline 
(Sigma Chemical Co.) were dissolved in physiological saline to appropriate volumes. DMSO 
solution was prepared by dissolving the same volume used to dilute the plant material, in 
physiological saline to an appropriate volume. 
 
Acetic acid, indomethacin, paracetamol and DMSO were administered intraperitoneally (i.p.) 
to all mice. Acetic acid was administered in a volume of 0.25 ml to mice. Indomethacin, 
paracetamol, pentoxifylline and DMSO were administered intraperitoneally to all the rats. 
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Carrageenan was injected into the subplantar surface of the right hind paws of the rats. E. 
coli, lipopolysaccharide, was administered intramuscularly (i.m.) into the thighs of rats. Fresh 
drug solutions were prepared each morning of the experiment. All drugs were administered in 
a volume of 1 ml/100 g of the body weight of animals. Control animals received equal 
volume injections of the appropriate vehicle. The doses and pre-treatment times of the plant 
extract and standard drugs were obtained from preliminary studies conducted in our 
laboratory. The pre-treatment times prior to the administration of 3 % acetic acid were 15 min 
(plant extract), 15 min (paracetamol) and 30 min (indomethacin). The pre-treatment times 
prior to the administration of carrageenan were 15 min (plant extract) and 30 min 
(indomethacin). The pre-treatment times prior to the administration of E. coli were 15 min 
(plant extract), 15 min (paracetamol) and 15 min (pentoxifylline). The pre-treatment time 
prior to the administration of either acetic acid, carrageenan or E. coli was 15 min (DMSO). 
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3.5. Pharmacological screening 
3.5.1. Assessment of the Antinociceptive activity of R. graveolens 
3.5.1.1. Acetic-acid writhing test 
The methods of Garcia et al. (2004); Williamson et al. (1996) and Koster et al. (1959) were 
used to assess the antinociceptive activity of R. graveolens. Mice were used in groups of 
eight per dose of plant extract, standard drugs, physiological saline or DMSO. The animals 
were kept individually in transparent Perspex mouse cages before the commencement of the 
experiment. Control mice were pre-treated with physiological saline and after 15 min each 
mouse was injected intraperitoneally with 0.25 ml of 3 % acetic acid. 5 min after the 
administration of acetic acid, the animals were observed and writhes were counted for 30 
min. The experiment was repeated using other groups of animals which were pre-treated for 
15 min with graded doses of plant extract, paracetamol or indomethacin prior to injecting 
them with 0.25 ml of 3 % acetic acid. All the experiments were performed in the 
pharmacology laboratory between 09h00 and 17h00. The ability of the plant extract to 
significantly reduce the number of acetic acid-induced writhes was taken as antinociceptive 
activity. 
 
3.5.1.2. Hot-plate test 
The methods of Williamson et al. (1996) and Eddy and Leimback (1953) were used. Mice 
were used in groups of eight per dose of plant extract, physiological saline or DMSO. The 
animals were kept individually in transparent Perspex mouse cages before the 
commencement of the experiment. Control mice were pre-treated with physiological saline 
and after 15 min each mouse was placed in an analgysiometer (TIIC, USA) maintained at 
55°C. The pain threshold is considered to be reached when the animals lift and lick their hind 
paws or attempt to jump out of the beaker. The time taken for animals to exhibit these 
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characteristics was noted by means of the ‘STOP’ button on the analgysiometer. The animals 
were tested before and then 15 min, 30 min, 45 min and 60 min after intraperitoneal 
administration of physiological saline. The experiment was repeated using other groups of 
animals which were tested before and then 15 min, 30 min, 45 min and 60 min after the 
administration of graded doses of plant extract. All the experiments were performed in the 
pharmacology laboratory between 09h00 and 17h00. The ability of the plant extract to delay 
the reaction time was taken as antinociceptive activity. 
 
3.5.2. Assessment of the Anti-inflammatory activity of R. graveolens  
3.5.2.1. Rat paw oedema test 
The modified method of Williamson et al. (1996) was used to assess the anti-inflammatory 
activity of R. graveolens. Rats were used in groups of 6 per dose of plant extract, standard 
drug, physiological saline, or DMSO. The animals were kept individually in transparent 
Perspex rat cages before the commencement of the experiment. Control animals were pre-
treated for 15 min with 0.25 ml (i.p.) of physiological saline. Acute inflammation or oedema 
was induced by injecting 0.1 ml of 1 % carrageenan into the subplantar surface of the right 
hind paw of the rat. Inflammation or oedema following carrageenan injection was noticeable 
within 30 min. The volume of the right hind paw was measured before and then after the 
injection of carrageenan at 30 min intervals for 4 h by volume displacement method using 
plethysmometer (TIIC, USA). The experiment was repeated using other groups of animals 
which were pre-treated with graded doses of plant extract, standard drug or DMSO. The 
volumes of the untreated rats’ right hind paws were also measured at 30 min intervals for 4 h. 
Acute inflammation or oedema was expressed as a mean increase in paw volume with respect 
to physiological saline control. All the experiments were performed in the pharmacology 
laboratory between 09h00 and 17h00. The ability of the plant extract to attenuate the paw 
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oedema was taken as an indication of anti-inflammatory activity. Inhibition was expressed as 
a percentage increase or decrease in oedema volume (Williamson et al., 1996).   
 
3.5.3. Assessment of the Antipyretic activity of R. graveolens 
3.5.3.1. E. coli-induced pyrexia test 
The method of Santos and Rao (1998) was modified for the antipyretic activity assessment of 
R. graveolens. Rats were used in groups of six per dose of plant extract, standard drug, 
physiological saline or DMSO. The animals were kept individually in transparent Perspex rat 
cages before the commencement of the experiment. Control animals were pre-treated for 15 
min with 0.25 ml (i.p.) of physiological saline. Pyrexia was induced with 50 µg/kg of E. coli 
administered intramuscularly (i.m.) into the thighs of the animals. The rectal temperature was 
measured before and after the administration of E. coli at 1 h intervals for a period of 5 h with 
a digital thermometer (TIIC, USA), inserted 2.3 cm into the rectum of the rat. The experiment 
was repeated using other groups of animals which were pre-treated with graded doses of plant 
extract, standard drugs or DMSO. The rectal temperatures of the untreated rats were also 
measured at 1 h intervals for 5 h. The increase of at least 1°C above the normal temperature 
after the administration of E. coli was taken as pyrexia (Amabeoku et al., 2010; Santos and 
Rao, 1998). The rectal temperatures of normothermic rats were also measured at 1 h intervals 
for 5 h. The effects of the different doses of plant extracts used were also evaluated alone on 
the rectal temperature of normothermic rats. All the experiments were performed in the 
pharmacology laboratory between 09h00 and 17h00. The ability of the plant extract to 
attenuate E.coli-induced pyrexia was taken as an indication of antipyretic activity. 
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3.6. HPLC analysis 
Chromatographic system: Beckman HPLC system consisting of a double pump 
Programmable Solvent Module model 126; Diode Array detector module model 160; 
Samsung computer 386 with management System Gold (V601) software applied by 
Beckman; column. C18 Bondapak 5 µm and dimensions (250 x 4.6 mm
2
). 
Chromatographic conditions: Mobile phase, solvent A: 1 % acetic acid; solvent B: methanol, 
Mode: gradient flow rate, 1 min/min; injection volume, 10 µl; detector, UV at 350 nm. The 
HPLC operating conditions were programmed to give the following: 0 min, solvent B: 20 %; 
5 min, solvent B: 40 %; 15 min, solvent B: 60 %; 20 min, solvent B: 80 % and 27 min. The 
run rate was 30 min.  
 
3.7. Acute toxicity 
The methods described by Lorke (1983) and modified by Ojewole (2006) were used to 
determine the median (LD50) of the plant extract. Mice were fasted for 16 hrs and then 
randomly divided into groups of eight per cage. Graded doses of the plant extract (100, 400, 
800, 1200, 1600, 2000, 2400, 2800, 3200, 3600, 4000 kg-1) were separately administered 
orally to mice in each test group by means of a bulbed steal needle. Control mice were pre-
treated orally with 0.25 ml of physiological saline by means of a bulbed steel needle. The 
mice were allowed free access to food and water and observed for 5 days for signs of acute 
toxicity or death. If death was recorded within the period of observation, log dose-response 
curves would be constructed for the plant extract from which the median lethal dose would be 
calculated.  
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3.8. Statistical analysis 
The data obtained for the antinociceptive, anti-inflammatory and antipyretic activities were 
analysed using one way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test (GraphPad Prism, version 5.0, GraphPad Software, Inc., San Diego CA 
92130, USA) and presented as Mean ± Standard Error Mean (SEM). P values of less than 5 
% (P < 0.05) were considered to be significant. 
 
3.9. Ethical considerations 
All experimental protocol used in this study were approved (12/2/23), by the University of 
the Western Cape Ethics Committee, Bellville 7535, South Africa and conformed to the 
University’s Regulation Act concerning animal experiments.   
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CHAPTER 4 
RESULTS 
 
4.1. Phytochemical analysis 
Data obtained from the phytochemical analysis of R. graveolens indicated the presence of the 
following chemical components: alkaloids, cardiac glycosides, flavonoids, saponins, tannins, 
and triterpene steroids. However, the test performed showed that the leaves of R. graveolens 
did not contain quinones (Table 1). 
 
Table 1. Phytochemical analysis of R. graveolens 
Chemical Components             Results 
Alkaloids        + 
Cardiac glycosides       + 
Flavonoids        + 
Quinones        - 
Saponins        + 
Tannins        + 
Triterpene steroids       + 
Key 
+ (Positive) means present 
-  (Negative) means absent 
 
 
 
 
29 
 
4.2. Pharmacological screening 
4.2.1. Antinociceptive activity 
4.2.1.1. Acetic acid writhing test 
Three percent (3 %) acetic acid (0.25 ml) produced a significant number of writhes in control 
mice that were pre-treated with physiological saline (0.25 ml, i.p.). The leaf methanol extract 
of R. graveolens (100 mg/kg, i.p.) significantly reduced the number of acetic acid-induced 
writhes by 54 %. Similarly, indomethacin (20 mg/kg, i.p.) and paracetamol (500 mg/kg, i.p.) 
profoundly reduced the number of writhes induced by 0.25 ml (i.p.) of 3 % acetic acid by 57 
% and 80 %, respectively. The plant extract (25, 50, 200 and 400 mg/kg, i.p.), 10 mg/kg (i.p.) 
of indomethacin and DMSO (0.25 ml, i.p.) did not significantly alter the writhes induced by 
0.25 ml (i.p.) of 3 % acetic acid. R. graveolens (25 mg/kg, i.p.) produced 39 % inhibition of 3 
% acetic acid-induced writhes whereas 50, 200 and 400 mg/kg (i.p.) of the plant extract, 
indomethacin (10 mg/kg, i.p.) and DMSO (0.25 ml, i.p.) produced 40 %, 31 %, 32 %, 20 % 
and 1 % inhibition of the acetic acid-induced writhes respectively. When combined, the 
lowest and sub-effective dose of the leaf methanol extract (25 mg/kg, i.p.) and the lowest and 
sub-effective dose of indomethacin (10 mg/kg, i.p.) significantly reduced the writhes induced 
by 0.25 ml of 3 % acetic acid in mice despite the individual doses having no significant 
effect. Together, both sub-effective doses produced 59 % inhibition of 3 % acetic acid-
induced writhes in mice (Table 2). 
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Table 2. Effect of R. graveolens on acetic acid-induced writhing in mice 
Treatment    Dose   Number of Writhes  Percentage 
Groups   (mg/kg) Mean ± SEM  inhibition (%) 
PS    -  26.0  1.94  - 
R. graveolens   25  15.75  3.16  39  
    50  15.5  0.5  40  
    100  12.0
*
  1.94  54  
    200  18.0  2.58  31  
    400  17.75  3.20  32  
Indomethacin   10  20.75  2.29  20  
    20  11.25
*
  2.94  57  
R. graveolens   25 
+ Indomethacin  10  10.75
*
  2.48  59  
Paracetamol   500  5.13
** 
 2.45  80  
DMSO    -  25.63  4.80  1  
 
*
p<0.05, 
**
p<0.001 compared to 3% acetic acid control (0.25 ml, i.p.), ANOVA (n = 8).  
Writhes are expressed as number of counts per 30 minutes.  
PS: Physiological saline 
DMSO: Dimethylsulfoxide 
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4.2.1.2. Hot-plate test 
Animals reacting to hot-plate thermal stimulation at 55°C were observed using parameters 
such as licking and/or lifting of hind paws, or attempting to jump out of the beaker. Mice pre-
treated with physiological saline reacted to hot-plate thermal stimulation. This occurred 
within 8.58 ± 0.73 sec in the first 15 min after administration of physiological saline (0.25 ml, 
i.p.) and within 6.85 ± 1.74 sec, 60 min later. The leaf methanol extract of R. graveolens (50 
mg/kg, i.p.) significantly delayed the reaction time of mice to hot-plate thermal stimulation 
30 min after treatment. R. graveolens (100 mg/kg, i.p.) significantly delayed the reaction time 
of mice to thermal stimulation 15, 30, and 60 min after treatment. R. graveolens (200 mg/kg, 
i.p.) significantly delayed the reaction time of mice 60 min after treatment. R. graveolens 
(400 mg/kg, i.p.) significantly delayed the reaction time in mice to thermal stimulation 15, 
30, 45, and 60 min after treatment. The plant extract (25 mg/kg, i.p.) and DMSO (0.25 ml, 
i.p.) did not significantly affect the reaction time of mice to hot-plate thermal stimulation 
(Table 3). 
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Table 3. Effect of R. graveolens on hot-plate induced nociception in mice 
Treatment   Dose     Reaction time (s) 
groups  (mg/kg)        0 min      15 min    30 min   45 min         60 min 
PS  0.25 ml        8.48±0.32        8.58±0.73        8.48±0.64       10.50±1.81       6.85±1.74 
R. graveolens 25        6.85±0.95        9.70±0.41       10.39±0.87      10.89±0.33      9.19±0.52 
  50        8.85±0.38        9.76±0.54       16.18±0.80
**
    8.77±0.67        7.26±0.51 
  100        9.19±0.72       12.88±0.62
*
     14.22±0.26
**
    9.94±0.39       11.25±0.25
* 
  200        6.85±1.00        9.84±0.78        9.90±0.69        9.85±0.44       11.79±0.66
** 
  400        8.48±0.11       13.93±0.68
**
    14.50±0.51
**
   15.58±0.35
*
    12.05±0.35
** 
DMSO  0.25 ml        9.77±1.12       10.54±1.51      10.06±1.09      8.16±1.60        7.66±0.36 
 
*
p<0.05, 
**
p<0.025 compared to physiological saline control, ANOVA (n = 8).  
The reaction time in seconds is expressed as Mean±SEM. 
PS: Physiological saline  
DMSO: Dimethylsulfoxide 
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4.3. Anti-inflammatory activity 
4.3.1. Rat paw oedema test 
One percent (1 %) carrageenan injected into the subplantar of the right hind paws of the rats 
pre-treated with physiological saline induced acute inflammation or oedema in the paws 
within 30 min which was also the peak time of the oedema. The leaf methanol extract of      
R. graveolens  (50 – 400 mg/kg, i.p.) significantly reduced the carrageenan-induced oedema 
over the 4 h period of testing. Indomethacin (10 mg/kg, i.p.) significantly reduced the 
carrageenan-induced oedema over the 4 h period of testing. The plant extract (25 mg/kg, i.p.) 
and indomethacin 2 mg/kg (i.p.) did not significantly affect the oedema elicited by 1 % 
carrageenan in the rats’ right hind paws. However, when combined, the lowest dose of R. 
graveolens (25 mg/kg, i.p.) and the lowest dose of indomethacin (2 mg/kg, i.p.) produced a 
significant reduction in carrageenan-induced oedema over the 4 h period of testing. DMSO 
(0.25 ml, i.p.) did not significantly affect the carrageenan-induced oedema in rats (Table 4). 
 
 
 
 
 
 
 3
4
 
Table 4. Effect of R. graveolens on carrageenan-induced oedema in the right hind paw of rat 
Treatment          Dose             Paw volume (ml)(Mean ± SEM) 
group            (mg/kg)            0 (min)        30               60           90      120              150             180             210              240 
UR                 -             0.65±0.02   0.52±0.02   0.58±0.05   0.62±0.03   0.62±0.03    0.68±0.05   0.72±0.06   0.72±0.10    0.75±0.03                   
PS                    0.25 ml     0.72±0.10   1.53±0.27   1.28±0.18   1.52±0.16    1.35±0.10   1.27±0.11   1.28±0.15   1.32±0.80    1.30±0.65     
R. graveolens     25           0.75±0.07   1.47±0.11   1.12±0.20   1.45±0.08    1.13±0.16   1.23±0.10   1.31±0.14   1.28±0.16    1.25±0.08 
                50           0.68±0.05   0.92±0.06
*
  0.80±0.07   0.90±0.10
*
  0.73±0.05
*
  0.73±0.04
*
  0.77±0.07
*
  0.68±0.07
*
  0.63±0.06
* 
               100          0.62±0.03   0.72±0.06
*
  0.75±0.03
*
  0.70±0.05
*
  0.70±0.06
*
  0.63±0.02
*
  0.67±0.07
* 
 0.53±0.04
*
  0.57±0.03
* 
               200          0.58±0.05   0.68±0.09
*
  0.72±0.03
*
  0.70±0.07
*
  0.63±0.04
*
  0.60±0.02
*
  0.63±0.08
*
  0.63±0.09
*
  0.57±0.05
* 
               400          0.33±0.02   0.42±0.03
*
  0.45±0.03
*
  0.42±0.03
*
  0.35±0.02
*
  0.35±0.02
*
  0.37±0.03
*
  0.33±0.06
*
  0.33±0.03
* 
Indomethacin      2            0.62±0.03   1.28±0.03   1.15±0.09   1.90±0.04    1.25±0.08   1.28±0.08    1.21±0.07   1.25±0.05   1.30±0.07 
               10           0.53±0.02   0.58±0.05
*
  0.68±0.05
*
  0.68±0.06
*
  0.62±0.03
*
  0.60±0
*
       0.57±0.03
*
  0.53±0.05
*
  0.52±0.04
* 
R. graveolens +  25              
Indomethacin      2            0.63±0.02   0.88±0.04
*
  0.87±0.02   0.70±0.05
*
  0.55±0.06
*
  0.45±0.03
*
  0.47±0.05
*
  0.47±0.07
*
  0.40±0.03
* 
DMSO            0.25 ml       0.62±0.10   1.52±0.12   1.30±0.07   1.53±0.09    1.35±0.08   1.28±0.09   1.27±0.11   1.27±0.13    1.35±0.03 
 
*
p<0.05 compared to physiological saline control, ANOVA (n = 6)  
UR: Untreated rats 
PS: Physiological saline 
DMSO: Dimethylsulfoxide 
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4.4. Antipyretic activity 
4.4.1. E. coli-induced pyrexia 
Normothermic rats showed mean rectal temperatures ranging from 35.2±0.35 ºC within the 
1
st
 hour of measurement up to 36.0±0.43 ºC at the 5
th
 hour of measurement. E. coli (50 μg/kg, 
i.m.) produced a time-dependent increase in the mean rectal temperature in rats pre-treated 
with physiological saline. R. graveolens (100 – 400 mg/kg, i.p.) significantly reduced E. coli-
induced pyrexia over the 5 h period of testing. Pentoxifylline (50 mg/kg, i.p.) also 
significantly reduced E. coli-induced pyrexia over the 5 h period of testing. R. graveolens (25 
mg/kg, i.p.) and pentoxifylline (10 mg/kg, i.p.) did not significantly alter the mean rectal 
temperatures of rats over the 5 h period of measurement. When combined, the lowest dose of 
R. graveolens (25 mg/kg, i.p.) and the lowest dose of pentoxifylline (10 mg/kg, i.p.) produced 
a significant reduction in pyrexia induced by E. coli (50 μg/kg, i.m.) over the 5 h period of 
measurement. Paracetamol (500 mg/kg, i.p.) and DMSO (0.25 ml, i.p.) did not significantly 
affect E. coli-induced pyrexia in rats over the 5 h period of measurement (Figure 1). The leaf 
methanol extract of R. graveolens (400 mg/kg, i.p.) significantly reduced the mean rectal 
temperature in normothermic rats over the 5 h period of measurement. 25 – 200 mg/kg (i.p.) 
of R. graveolens did not affect the mean rectal temperatures of normothermic rats over the    
5 h period of measurement (Figure 2). 
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Figure 1. Effect of R. graveolens, paracetamol, pentoxifylline on lipopolysaccharide (E. coli)-induced pyrexia in rats 
PS: Physiological saline 
LP: Lipopolysaccharide 
RG: R. graveolens 
DMSO: Dimethylsulfoxide  
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Figure. 2. Effect of R. graveolens on the rectal temperature of normothermic rats 
RG: R. graveolens 
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4.5. Acute toxicity study 
The acute toxicity study did not show any deaths or signs of acute toxicity in mice following oral 
administration of 100 – 4000 mg/kg of the leaf extract of R. graveolens. The 4000 mg/kg (p.o.) 
dose of the plant extract was therefore, the no-adverse-effect-level (NOAEL). The LD50 obtained 
for the plant species may probably be greater than 4000 mg/kg (p.o.) in mice. 
 
4.6. HPLC analysis 
The HPLC fingerprint of the plant species obtained revealed major characteristic peaks at the 
following retention times (minutes): 1.654, 2.271, 2.403, 4.705 and 7.691 (Figure 3). 
 
 
 
 
Figure 3. HPLC fingerprint of R. graveolens 
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CHAPTER 5 
DISCUSSION 
 
The results of the study indicate that R. graveolens has antinociceptive, anti-inflammatory and 
antipyretic activities. Two models namely, the acetic acid writhing test and the hot-plate test, 
were used to investigate the peripheral and central antinociceptive activities of R. graveolens, 
respectively, in mice. The carrageenan-induced rat paw oedema test was used to investigate anti-
inflammatory activity of the plant extract in rats. E.coli-induced pyrexia was used to investigate 
the antipyretic activity of the plant extract in rats. 
 
In this study, the leaf methanol extract of R. graveolens significantly antagonised the acetic acid-
induced writhing in mice. Similarly, indomethacin and paracetamol significantly antagonised 
acetic acid writhing in mice. In addition, sub-effective doses of R. graveolens and indomethacin 
combined significantly antagonised acetic acid-induced writhing in mice. Satyanaraya et al. 
(2004) has shown that acetic acid induces writhing by stimulating the production of 
prostaglandins. Standard analgesic drugs, indomethacin and paracetamol, have been shown to 
inhibit prostaglandin synthesis in the brain (Rang et al., 2012; Flower and Vane, 1972). 
Therefore, it is not surprising that both indomethacin and paracetamol significantly antagonised 
acetic acid-induced writhing. Since R. graveolens and also the combined therapy of sub-effective 
doses of R. graveolens and indomethacin antagonised acetic acid-induced writhes, it is possible 
to suggest that the plant extract may be producing antinociceptive activity through the 
manipulation of the prostaglandin system.  
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The leaf methanol extract of R. graveolens significantly delayed the reaction time of mice to 
thermal stimulation produced by the hot-plate. Morphine, a standard centrally acting analgesic 
drug, is known to attenuate nociception produced by the hot-plate (Amabeoku et al., 2012). It is 
therefore, possible that R. graveolens may be acting through certain central pain receptors to 
delay nociception produced by hot-plate in the study. Williamson et al. (1996), Koster et al. 
(1959), and Eddy and Leimback (1953), stipulated that the acetic acid writhing and hot-plate 
tests are used to evaluate peripherally and centrally acting analgesic drugs. Since R. graveolens 
significantly antagonised both acetic acid-induced writhing and thermal stimulation produced by 
hot-plate, it is tempting to suggest that the plant species has both peripheral and central 
antinociceptive activities. 
 
In the present study, the leaf methanol extract of R. graveolens profoundly reduced carrageenan-
induced rat paw oedema. Indomethacin also antagonised carrageenan-induced rat paw oedema. 
In addition, sub-effective doses of R. graveolens and indomethacin combined significantly 
antagonised carrageenan-induced rat paw oedema. Carrageenan induces rat paw oedema due to 
histamine, serotonin, bradykinin and prostaglandin like substances (Vinegar et al., 1969). 
Perianayagam et al. (2006), Adedapo et al. (2008) and Swingle (1974), have shown that 
mediators such as prsotaglandins, bradykinin, histamine and serotonin are implicated at different 
phases of carrageenan-induced rat paw oedema. Capasso et al. (1975) and Di Rosa et al. (1971) 
have also reported the implication of histamine, 5-hydroxytryptamine, bradykinin, nitric acid, 
and prostaglandins in carrageenan-induced rat paw oedema. The carrageenan-induced rat paw 
oedema test is known to be sensitive to cyclo-oxygenase (COX) inhibitors, and may also be used 
to evaluate the effect of NSAIDs (Rao et al., 2005). COX – 1 and COX – 2 enzymes interact to 
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form prostaglandins. In inflamed tissue, COX – 2 is unregulated. This may be responsible for the 
enhanced production of prostaglandins (Ratheesh et al., 2009). In a study conducted by Ratheesh 
et al. (2009), the reduction of rat paw oedema and the reduced activity of COX – 2 indicated 
anti-inflammatory effects. Amabeoku et al. (2012), reported that C. orbiculata reduced 
carrageenan-induced rat paw oedema, and suggested that the plant may have affected 
inflammatory mediators to produce its anti-inflammatory activity. Also, indomethacin produces 
anti-inflammatory effects by inhibiting COX, thus inhibiting prostaglandin synthesis (Rang et al., 
2012). The data on the anti-inflammatory activity of R. graveolens in the present study are in 
agreement with those of Amabeoku et al. (2012). 
 
In the present study, the leaf methanol extract of R. graveolens alone significantly reduced the 
rectal temperature in normothermic rats. R. graveolens also significantly reduced pyrexia 
induced by the lipopolysaccharide (LPS) or bacterial endotoxin, E. coli. In addition, 
pentoxifylline significantly reduced E. coli-induced pyrexia in rats. Furthermore, combined 
therapy of sub-effective doses of R. graveolens and pentoxifylline antagonised E. coli-induced 
pyrexia. According to Kluger (1991), lipopolysaccharide can induce fever in rats. This may be 
due to prostaglandins and cytokines such as interleukin (IL) - 1β, IL - 6 and tumor necrosis factor  
(TNF) – α. Flower and Vane (1972), found that the antipyretic activity of paracetamol is 
produced by the inhibition of prostaglandin synthetase. This results in the blockade of 
prostaglandin synthesis in the brain. In this study, paracetamol, an analgesic and antipyretic drug, 
did not significantly affect E. coli-induced pyrexia in rats. While it is believed that 
prostaglandins regulate body temperature (Dascombe, 1985), studies suggest that pyrexia 
produced by LPS in rats, guinea-pigs and rabbits implicated the stimulation of TNF – α (Roth 
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and Zeisberger, 1995; Kluger, 1991; LeMay et al., 1990). This may explain why paracetamol did 
not significantly affect E. coli-induced pyrexia in rats. Pentoxifylline is a TNF–α antagonist 
(Marcinkiewicz et al., 2000; LeMay et al., 1990). It is not surprising therefore, that pentoxifylline 
antagonised pyrexia induced by LPS in this study.  This is in agreement with the findings of 
Santos and Rao (1998), which show that pentoxifylline reduced pyrexia induced by LPS. Since 
R. graveolens and also the combined therapy of sub-effective doses of R. graveolens and 
pentoxifylline antagonised E. coli-induced pyrexia, it is probable that TNF-α inhibition may 
underpin the antipyretic activity of the plant species.  
 
The phytochemical tests carried out on the powdered leaf of R. graveolens indicated the presence 
of alkaloids, cardiac glycosides, flavonoids, saponins, tannins, and triterpine steroids. Israili 
(2009) has reported that saponins and flavonoids have analgesic and antipyretic activity. 
Bruneton (1995) reported that saponins have analgesic and anti-inflammatory activities. Pendota 
et al. (2009), conducted a study on the use of H. pauciflorus in inflammation, pain and fever and 
suggested that these activities may be due to the presence of tannins, flavonoids, steroids and/or 
terpenes. Another study by Ojewole (2005), speculated that the presence of flavonoids and 
triterpenoids in B. pinnatum may account for the plant species’ antinociceptive and anti-
inflammatory activities. According to Kotb (1985) and Benazir et al. (2011), R. graveolens 
contains volatile oils, resins and flavonoids. Flavonoids isolated from other plant extracts have 
proven to possess analgesic activity. Since plant samples with similar HPLC fingerprints have 
similar properties (Fan et al., 2006), the presence of flavonoids found in the leaf methanol extract 
of R. graveolens may be suggestive that the antinociceptive activity produced is due to the 
content of flavonoids. Also, since R. graveolens contains other secondary metabolites such as 
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saponins and triterpene steroids, it is possible that these metabolites may be contributing to the 
antinociceptive, anti-inflammatory and antipyretic activities of the plant species in this study. 
 
The HPLC fingerprint obtained for R. graveolens revealed characteristic peaks at the following 
retention times (minutes): 1.654 min, 2.271 min, 2.403 min, 4.705 min and 7.691 min. The acute 
toxicity test carried out revealed that the LD50 value obtained for the plant species after oral 
administration may be greater than 4000mg/kg. This high LD50 indicates that R. graveolens is 
non-toxic and/or safe in mice.  
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CHAPTER 6 
CONCLUSION 
 
The data obtained in this study indicate that R. graveolens has antinociceptive, anti-inflammatory 
and antipyretic activity which may be due to the plant species inhibiting mediators implicated in 
pain, inflammation and fever. The role of saponins, flavonoids and triterpene steroids suggest 
that these secondary metabolites may contribute to the antinociceptive, anti-inflammatory and 
antipyretic activities of R. graveolens. The relatively high LD50 value of 4000 mg/kg (p.o.) 
obtained for the plant species indicates that it may be non-toxic to/or safe in mice. The results 
obtained substantiate the use of the plant species by traditional medicine practitioners in South 
Africa for the management and treatment of essential events such as pain, inflammation and 
fever. Further studies are needed to elucidate the full mechanisms of antinociceptive, anti-
inflammatory and antipyretic activities of R. graveolens. In addition, further toxicological studies 
are needed to determine the safety profile of R. graveolens. 
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